Surface receptor-targeted protein-based nanocarriers for drug delivery: advances in cancer therapy

Surface receptor-targeted protein-based nanocarriers for drug delivery: advances in cancer therapy Panneerselvam Theivendren http://orcid.org/0000-0002-8197-4688 Parasuraman Pavadai http://orcid.org/0000-0002-0779-4750 Suganthan Veerachamy http://orcid.org/0000-0002-3657-7026 Ponnusamy Palanisamy http://orcid.org/0000-0001-7005-9604 Selvaraj Kunjiappan http://orcid.org/0000-0002-6741-5118 Abstract

Significant progress has been made in cancer therapy with protein-based nanocarriers targeted directly to surface receptors for drug delivery. The nanocarriers are a potentially effective solution for the potential drawbacks of traditional chemotherapy, such as lack of specificity, side effects, and development resistance. Peptides as nanocarriers have been designed based on their biocompatible, biodegradable, and versatile functions to deliver therapeutic agents into cancer cells, reduce systemic toxicity, and maximize therapy efficacy through utilizing targeted ligands such as antibodies, amino acids, vitamins, and other small molecules onto protein-based nanocarriers and thus ensuring that drugs selectively accumulate in the cancer cells instead of healthy organs/drug release at a target site without effects on normal cells, which inherently caused less systemic toxicity/off-target effect. Moreover, their intrinsic protein backbone naturally degrades in vivo , providing another level of safety over synthetic materials. Various issues like immunogenicity, mass production, and quality control must be addressed for widespread use. However, further studies are necessary to perfect protein engineering and improve drug loading, protein modification, and targeting. Thus, it can be concluded that protein-based nanocarriers targeted against the surface receptors would help achieve cancer management in a more focused manner, thus minimizing toxicity. The further development of these nanoparticles could bring a significant change in cancer treatment so that more personalized, targeted, and safe therapies would be available to all patients.
01 30 2025 03 24 2025 122003 10.1088/crossmark-policy iopscience.iop.org Surface receptor-targeted protein-based nanocarriers for drug delivery: advances in cancer therapy Nanotechnology paper © 2025 IOP Publishing Ltd. All rights, including for text and data mining, AI training, and similar technologies, are reserved. 2024-11-03 2025-01-23 2025-01-30 https://iopscience.iop.org/page/copyright https://iopscience.iop.org/info/page/text-and-data-mining 10.1088/1361-6528/adad7a https://iopscience.iop.org/article/10.1088/1361-6528/adad7a https://iopscience.iop.org/article/10.1088/1361-6528/adad7a/pdf https://iopscience.iop.org/article/10.1088/1361-6528/adad7a/pdf https://iopscience.iop.org/article/10.1088/1361-6528/adad7a/pdf https://iopscience.iop.org/article/10.1088/1361-6528/adad7a/pdf https://iopscience.iop.org/article/10.1088/1361-6528/adad7a https://iopscience.iop.org/article/10.1088/1361-6528/adad7a/pdf https://iopscience.iop.org/article/10.1088/1361-6528/adad7a https://iopscience.iop.org/article/10.1088/1361-6528/adad7a/pdf Int. J. Pharm. Sci. Singh 10.5281/zenodo.8266559 2 59 2023 Cancer: unraveling the complexities of uncontrolled growth and metastasis PEXACY Mol. Asp. Med. Bertram 10.1016/S0098-2997(00)00007-8 21 167 2000 The molecular biology of cancer Compton 10.1007/978-3-030-40651-6_1 1 2020 The Nature and Origins of Cancer Ghufran 1429 2023 CA Cancer J. Clin. Bray 10.3322/caac.21834 74 229 2024 Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries EClinicalMedicine Fan 10.1016/j.eclinm.2022.101673 54 2022 Stark differences in cancer epidemiological data between GLOBOCAN and GBD: emphasis on oral cancer and wider implications Horiz. Cancer Res. Baykara 57 105 2015 Current therapies and latest developments in cancer treatment Cancer Res. Frei III 45 6523 1985 Curative cancer chemotherapy Gustafson 157 2013 Mater. Sci. Eng. C Krukiewicz 10.1016/j.msec.2016.01.063 62 927 2016 Biomaterial-based regional chemotherapy: local anticancer drug delivery to enhance chemotherapy and minimize its side-effects Pharmaceuticals Garcia-Oliveira 10.3390/ph14020157 14 157 2021 Status and challenges of plant-anticancer compounds in cancer treatment Acta Pharm. Sin. B He 10.1016/j.apsb.2021.03.008 11 3379 2021 Advances and challenges in the treatment of esophageal cancer Chem. Rev. Ward 10.1021/acs.chemrev.0c00383 121 3297 2020 Challenges and opportunities in cancer drug resistance Eur. J. Med. Chem. Song 10.1016/j.ejmech.2022.114205 232 2022 Therapeutic strategies to overcome cisplatin resistance in ovarian cancer Cancer Drug Resist. Ulldemolins 10.20517/cdr.2020.59 4 44 2021 Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics Molecules Adepu 10.3390/molecules26195905 26 5905 2021 Controlled drug delivery systems: current status and future directions Biomater. Res. Sung 10.1186/s40824-020-00190-7 24 12 2020 Recent advances in polymeric drug delivery systems Drug Dev. Res. Kunjiappan 10.1002/ddr.21758 82 309 2021 Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: a state‐of‐the‐art review Adv. Ther. Large 10.1002/adtp.201800091 2 2019 Advances in receptor‐mediated, tumor‐targeted drug delivery Özören 135 2003 Cell surface death receptor signaling in normal and cancer cells Cell Commun. Signal. Planque 10.1186/1478-811X-4-7 4 1 2006 Nuclear trafficking of secreted factors and cell-surface receptors: new pathways to regulate cell proliferation and differentiation, and involvement in cancers Breast Cancer Res. Treat. Rashid 10.1007/s10549-016-4044-0 161 191 2017 Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan Cancer Cell Weischenfeldt 10.1016/j.ccr.2013.01.002 23 159 2013 Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer Rep. Prog. Phys. Bongrand 10.1088/0034-4885/62/6/202 62 921 1999 Ligand-receptor interactions Proc. Natl Acad. Sci. Helm 10.1073/pnas.88.18.8169 88 8169 1991 Measurement of ligand-receptor interactions Langmuir Clemons 10.1021/acs.langmuir.8b02946 34 15343 2018 Distinction between active and passive targeting of nanoparticles dictate their overall therapeutic efficacy Expert Opin. Drug Deliv. Sakurai 10.1517/17425247.2015.955847 12 41 2015 Advances in an active and passive targeting to tumor and adipose tissues J. Med. Chem. Langlois 10.1021/jm020099f 46 319 2003 5-HT4 receptor ligands: applications and new prospects Neuropharmacol Pauwels 1083 38 2003 5-HT receptors and their ligands Nanotechnol Kunjiappan 10.1088/1361-6528/ab5c56 31 2020 Design, in silico modelling and functionality theory of folate-receptor-targeted myricetin-loaded bovine serum albumin nanoparticle formulation for cancer treatment Biomater Wagner 10.1016/j.biomaterials.2009.11.093 31 2388 2010 Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles J. Polym. Environ. Rajeshkumar 10.1007/s10924-024-03391-6 32 1 2024 Folate receptor-targeted camptothecin-loaded PLGA-glutenin nanoparticles for effective breast cancer treatment J. Biomater. Appl. Yao 10.1177/0885328216679571 31 832 2017 Folic acid-conjugated soybean protein-based nanoparticles mediate efficient antitumor ability in vitro Int. J. Boil. Macromol. Nosrati 10.1016/j.ijbiomac.2018.06.026 117 1125 2018 Folic acid conjugated bovine serum albumin: an efficient smart and tumor targeted biomacromolecule for inhibition folate receptor positive cancer cells Biomater Bae 10.1016/j.biomaterials.2011.10.050 33 1536 2012 Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types Drug Des. Dev. Ther. Mao 10.2147/DDDT.S296253 15 3475 2021 Transferrin-decorated protein-lipid hybrid nanoparticle efficiently delivers cisplatin and docetaxel for targeted lung cancer treatment Int. J. Nanomed. Taheri 10.2147/ijn.s23949 6 1863 2011 Use of biotin targeted methotrexate–human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy Int. J. Nanomed. Sun 10.2147/ijn.s181296 14 135 2019 Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy J. Mater. Sci. Pang 10.1007/s10853-018-2684-7 53 14907 2018 Folate-conjugated zein/Fe3O4 nanocomplexes for the enhancement of cellular uptake and cytotoxicity of gefitinib Isticato 10.1128/9781555819323.ch17 349 2016 Spore surface display Greenfield 2014 2nd edn Antibodies a laboratory manual Nat. Rev. Drug Discovery Keefe 10.1038/nrd3141 9 537 2010 Aptamers as therapeutics Biosens. Bioelectron. Tombelli 10.1016/j.bios.2004.11.006 20 2424 2005 Analytical applications of aptamers Chem. Rev. Cheng 10.1021/cr000045i 101 3219 2001 β-Peptides: from structure to function Trends Biotechnol. Lien 10.1016/j.tibtech.2003.10.005 21 556 2003 Therapeutic peptides J. Control Release Iqbal 10.1016/j.jconrel.2020.10.030 329 997 2021 Serum protein-based nanoparticles for cancer diagnosis and treatment J. Control Release Elzoghby 10.1016/j.jconrel.2012.04.036 161 38 2012 Protein-based nanocarriers as promising drug and gene delivery systems JAMA Oncol. Moasser 10.1001/jamaoncol.2015.2286 1 1154 2015 The evolving landscape of HER2 targeting in breast cancer Nat. Rev. Clin. Oncol. Oh 10.1038/s41571-019-0268-3 17 33 2020 HER2-targeted therapies—a role beyond breast cancer Mol. Oncol. Dienstmann 10.1016/j.molonc.2011.11.009 6 15 2012 Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer Mass Med. Soc. Messersmith 10.1056/NEJMe0806778 359 1834 2008 Targeting EGFR in colorectal cancer Gynecol. Oncol. Kalli 10.1016/j.ygyno.2007.11.020 108 619 2008 Folate receptor alpha as a tumor target in epithelial ovarian cancer Cancer Metastasis Rev. Vergote 10.1007/s10555-014-9539-8 34 41 2015 Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications J. Pharm. Verma 10.1155/2018/9285854 2018 2018 Protein based nanostructures for drug delivery J. Pharmacol. Exper. Ther. Nagar 10.1124/jpet.123.001673 388 91 2024 Protein-based nanocarriers and nanotherapeutics for infection and inflammation J. Agric. Food Chem. Zhang 10.1021/acs.jafc.2c01936 70 6354 2022 Advances in protein-based nanocarriers of bioactive compounds: from microscopic molecular principles to macroscopical structural and functional attributes Stem Cells Kavari 10.1002/stem.3069 38 34 2020 Engineered stem cells targeting multiple cell surface receptors in tumors Pharmaceutics Rizwanullah 10.3390/pharmaceutics13122039 13 2039 2021 Receptor-mediated targeted delivery of surface-ModifiedNanomedicine in breast cancer: recent update and challenges Acc. Chem. Res. Kievit 10.1021/ar2000277 44 853 2011 Surface engineering of iron oxide nanoparticles for targeted cancer therapy Ann. Surg. Haier 10.1097/00000658-200001000-00003 231 11 2000 Cell surface molecules and their prognostic values in assessing colorectal carcinomas Mol. Pathol. Uings 10.1136/mp.53.6.295 53 295 2000 Cell receptors and cell signalling Curr. Med. Chem. Anticancer Agents Kunjiappan 10.2174/1871520619666190702145609 19 1966 2019 Design, in silico modelling, and functionality theory of novel folate receptor targeted rutin encapsulated folic acid conjugated keratin nanoparticles for effective cancer treatment Biomed. Phys. Eng. Express Kunjiappan 10.1088/2057-1976/aaa1cf 4 2018 Design, in silico modeling, biodistribution study of rutin and quercetin loaded stable human hair keratin nanoparticles intended for anticancer drug delivery Int. Nano Lett. Chowdhury 10.1007/s40089-017-0208-0 7 91 2017 Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases J. Polym. Environ. Rajeshkumar 10.1007/s10924-023-03107-2 32 2120 2024 Enhanced delivery of retinoic acid to breast cancer cells by folate receptor-targeted folic acid-conjugated glutenin nanoparticles for promising treatment of breast cancer Mini-Rev. Med. Chem. Arias 10.2174/138955711793564024 11 1 2011 Drug targeting strategies in cancer treatment: an overview Signal Transduct. Target Ther. Senapati 10.1038/s41392-017-0004-3 3 7 2018 Controlled drug delivery vehicles for cancer treatment and their performance Chauhan 105 2023 Biomaterial-based delivery systems for chemotherapeutics Expert Opin. Drug Deliv. Li 10.1517/17425247.2014.924500 11 1435 2014 Orally active-targeted drug delivery systems for proteins and peptides Expert Opin. Drug Deliv. Das 10.1517/17425240902780166 6 285 2009 Ligand-based targeted therapy for cancer tissue Pattni 3 2015 Targeted drug delivery systems: strategies and challenges Jain 10.1007/978-1-4939-9798-5_1 1 2020 (ed) An overview of drug delivery systems Pharmacol. Rep. Wilczewska 10.1016/S1734-1140(12)70901-5 64 1020 2012 Nanoparticles as drug delivery systems Adv. Drug Deliv. Rev. Nazli 10.1016/j.addr.2022.114502 189 2022 Strategies and progresses for enhancing targeted antibiotic delivery Int. J. Pharm. Martínez-López 10.1016/j.ijpharm.2020.119289 581 2020 Protein-based nanoparticles for drug delivery purposes Feingold 2024 Naunyn-Schmiedeberg’s Arch. Pharmacol. Rajeshkumar 10.1007/s00210-023-02480-y 396 2571 2023 Glucose-conjugated glutenin nanoparticles for selective targeting and delivery of camptothecin into breast cancer cells Pharmaceutics Soe 10.3390/pharmaceutics11110562 11 562 2019 Development of folate-functionalized PEGylated zein nanoparticles for ligand-directed delivery of paclitaxel J. Drug Deliv. Sci. Technol. Türkeş 10.1016/j.jddst.2023.105178 91 2024 Folic acid-conjugated cancer drug curcumin-loaded albumin nanoparticles: investigation of curcumin release kinetics Pharmaceutics Fuster 10.3390/pharmaceutics15041186 15 1186 2023 Folic acid-modified ibrutinib-loaded silk fibroin nanoparticles for cancer cell therapy with over-expressed folate receptor Cancer Nanotechnol. Liu 10.1186/s12645-021-00110-x 13 2 2022 Baicalin-loaded folic acid-modified albumin nanoparticles (FA-BSANPs/BA) induce autophagy in MCF-7 cells via ROS-mediated p38 MAPK and Akt/mTOR pathway J. Mater. Sci. Wang 10.1007/s10853-019-03486-9 54 8613 2019 Biotin-modified bovine serum albumin nanoparticles as a potential drug delivery system for paclitaxel Micro Perumal 10.3390/micro3010008 3 84 2023 Transferrin-grafted albumin nanoparticles for the targeted delivery of apocynin and neuroprotection in an in vitro model of the BBB Feingold 2022 Cancers Prajapati 10.3390/cancers13123011 13 3011 2021 Albumin-based nanoparticles for the delivery of doxorubicin in breast cancer Köten 2024 10.69860/nobel.9786053359289.3 Maize and Sorghum As Protein Sources Cereal Chem. Anderson 10.1094/CCHEM-06-10-0091 88 159 2011 Zein extraction from corn, corn products, and coproducts and modifications for various applications: a review Food Rev. Int. Li 10.1080/87559129.2021.2015377 39 4040 2023 Utilization of zein-based particles in Pickering emulsions: a review Front. Pharmacol. Liu 10.3389/fphar.2023.1120251 14 2023 Zein-based nanoparticles: preparation, characterization, and pharmaceutical application 3 Biotech Kunjiappan 10.1007/s13205-019-1720-x 9 1 2019 Modeling a pH-sensitive Zein-co-acrylic acid hybrid hydrogels loaded 5-fluorouracil and rutin for enhanced anticancer efficacy by oral delivery Angew. Chem., Int. Ed. Engl. Liu 10.1002/anie.202003708 60 11024 2021 Precision conjugation: an emerging tool for generating protein–polymer conjugates Adv. Drug Deliv. Rev. Stevens 10.1016/j.addr.2021.05.002 174 447 2021 Self-assembly of protein-polymer conjugates for drug delivery Smart Mater. Med. Dang 10.1016/j.smaim.2020.04.001 1 10 2020 Nanoparticle-based drug delivery systems for cancer therapy J. Control Release Kimiz-Gebologlu 10.1016/j.jconrel.2022.05.027 347 533 2022 Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake Adv. Funct. Mater. Huang 10.1002/adfm.202011171 31 2021 Nanomedicine‐boosting tumor immunogenicity for enhanced immunotherapy Front. Immunol. Shen 10.3389/fimmu.2022.1001263 13 2022 rAAV immunogenicity, toxicity, and durability in 255 clinical trials: a meta-analysis Int. J. Pharm. Makwana 10.1016/j.ijpharm.2020.120117 593 2021 Liposomal doxorubicin as targeted delivery platform: current trends in surface functionalization Nat. Rev. Cardiol. Sahoo 10.1038/s41569-020-00499-9 18 389 2021 Targeted delivery of therapeutic agents to the heart Ann. Oncol. Blinman 10.1093/annonc/mdr559 23 1104 2012 Preferences for cancer treatments: an overview of methods and applications in oncology J. Nucl. Med. Strauss 32 623 1991 The applications of PET in clinical oncology Acc. Chem. Res. Koo 10.1021/ar2000138 44 1018 2011 In vivo targeted delivery of nanoparticles for theranosis J. Control Release Kwon 10.1016/j.jconrel.2012.07.010 164 108 2012 Analysis on the current status of targeted drug delivery to tumors Nanotheranostics Li 10.7150/ntno.19380 1 346 2017 Be active or not: the relative contribution of active and passive tumor targeting of nanomaterials Adv. Drug Deliv. Rev. Torchilin 10.1016/j.addr.2010.03.011 63 131 2011 Tumor delivery of macromolecular drugs based on the EPR effect Mol. Pharm. Gocheva 10.1021/acs.molpharmaceut.9b00250 16 3293 2019 A look at receptor–ligand pairs for active-targeting drug delivery from crystallographic and molecular dynamics perspectives Drug Discov. Today Kaemmerer 10.1016/j.drudis.2020.11.030 26 663 2021 Addressing the tumour microenvironment in early drug discovery: a strategy to overcome drug resistance and identify novel targets for cancer therapy J. Am. Chem. Soc. Park 10.1021/jacs.7b11468 140 4244 2018 Addressing drug resistance in cancer with macromolecular chemotherapeutic agents Eur. J. Pharm. Sci. Krishna 10.1016/S0928-0987(00)00114-7 11 265 2000 Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Biomed. Pharmacother. Mohammad 10.1016/j.biopha.2018.02.038 100 335 2018 Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR Biochem. Pharmacol. Muley 10.1016/j.bcp.2020.113959 177 2020 Drug uptake-based chemoresistance in breast cancer treatment Stem Cell Res. Ther. Li 10.1186/s13287-022-02822-2 13 146 2022 Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects J. Clin. Oncol. Poon 10.1200/JCO.1991.9.11.1967 9 1967 1991 Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer Clin. Pharmacokinet. Gan 10.2165/00003088-200645090-00001 45 855 2006 Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation Br. J. Clin. Pharmacol. Venkatakrishnan 10.1111/bcp.12261 77 998 2014 Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment Cancer Metastasis Rev. Kerbel 10.1023/A:1013172910858 20 79 2001 Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches Cancers Postiglione 10.3390/cancers3022597 3 2597 2011 Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategies Int. J. Nanomed. Accardo 10.2147/IJN.S53593 9 1537 2014 Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs Nanomedicine Master 10.2217/nnm.12.160 7 1895 2012 EGF receptor-targeted nanocarriers for enhanced cancer treatment Adv. Drug Deliv. Rev. Li 10.1016/j.addr.2022.114462 189 2022 Self-assembling nanocarriers from engineered proteins: design, functionalization, and application for drug delivery Adv. Mater. Qin 10.1002/adma.201902791 31 2019 Rational design of nanocarriers for intracellular protein delivery Adv. Mater. Interfaces Amani 10.1002/admi.201900572 6 2019 Controlling cell behavior through the design of biomaterial surfaces: a focus on surface modification techniques Acta Biomater. Chouirfa 10.1016/j.actbio.2018.10.036 83 37 2019 Review of titanium surface modification techniques and coatings for antibacterial applications ChemMedChem Shonberg 10.1002/cmdc.201100101 6 963 2011 Design strategies for bivalent ligands targeting GPCRs Acta Biomater. Zhang 10.1016/j.actbio.2021.06.044 131 80 2021 2D biointerfaces to study stem cell–ligand interactions Expert Opin. Drug Deliv. Gubernator 10.1517/17425247.2011.566552 8 565 2011 Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity Die Pharmazie Xi 10.1691/ph.2021.0128 76 61 2021 Drug loading techniques for exosome-based drug delivery systems Adv. Drug Deliv. Rev. Doane 10.1016/j.addr.2012.05.012 65 607 2013 Nanoparticle mediated non-covalent drug delivery Expert Opin. Drug Deliv. Hassanin 10.1080/17425247.2020.1813713 17 1437 2020 Self-assembled non-covalent protein-drug nanoparticles: an emerging delivery platform for anti-cancer drugs Artif. Cells Nanomed. Biotechnol. Jain 10.1080/21691401.2018.1561457 47 524 2019 In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery Int. J. Nanomed. Manaia 10.2147/IJN.S133832 12 4991 2017 Physicochemical characterization of drug nanocarriers J. Am. Chem. Soc. Davis 10.1021/ja00193a024 111 3919 1989 Physicochemical properties of VPI-5 Crit. Rev. Food Sci. Nutr. Gharsallaoui 10.1080/10408398.2013.763765 56 1262 2016 Nisin as a food preservative: part 1: physicochemical properties, antimicrobial activity, and main uses Mater. Sci. Eng. C Nemani 10.1016/j.msec.2013.07.001 33 4453 2013 In vitro and in vivo evaluation of SU-8 biocompatibility Antimicrob. Agents Chemother. Oh 10.1128/AAC.40.6.1564 40 1564 1996 In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone Nat. Genet. Derks 10.1038/s41588-022-01174-0 54 1457 2022 Ten challenges for clinical translation in psychiatric genetics Adv. Drug Deliv. Rev. Younis 10.1016/j.addr.2021.114083 181 2022 Clinical translation of nanomedicines: challenges, opportunities, and keys J. Control Release Anderson 10.1016/S0168-3659(98)00178-3 57 107 1999 Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems Sci. Technol. Adv. Mater. Shiraishi 10.1080/14686996.2019.1590126 20 324 2019 Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review AAPS J. Desai 10.1208/s12248-012-9339-4 14 282 2012 Challenges in development of nanoparticle-based therapeutics Acta Pharm. Sin. B Shan 10.1016/j.apsb.2022.02.025 12 3028 2022 Current approaches of nanomedicines in the market and various stage of clinical translation Int. J. Nanomed. Borlan 10.2147/IJN.S295234 16 2147 2021 Interventional NIR fluorescence imaging of cancer: review on next generation of dye-loaded protein-based nanoparticles for real-time feedback during cancer surgery Pharmaceutics Ferraro 10.3390/pharmaceutics16091172 16 1172 2024 Exploring protein-based carriers in drug delivery: a review J. Control Release Danhier 10.1016/j.jconrel.2010.08.027 148 135 2010 To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Control Release Saul 10.1016/j.jconrel.2006.05.028 114 277 2006 A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers Nat. Rev. Clin. Oncol. Meric-Bernstam 10.1038/nrclinonc.2012.127 9 542 2012 Overcoming implementation challenges of personalized cancer therapy Nat. Rev. Clin. Oncol. Wistuba 10.1038/nrclinonc.2011.2 8 135 2011 Methodological and practical challenges for personalized cancer therapies